Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma

Published:2024-06 Issue:6 Volume:28 Page:867-869
ISSN:1091-255X
Container-title:Journal of Gastrointestinal Surgery
language:en
Short-container-title:Journal of Gastrointestinal Surgery

Author:

Lu Hao,Liu Jun-Feng^ORCID,Rong Yu,Liu Xin-Bo,Wang Yan

Publisher

Elsevier BV

Reference6 articles.

1. Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: A multi-center study;Yang;Chin J Cancer Res,2018

2. The treatment of resectable esophageal cancer in Guidelines in Chinese Society of Clinical Oncology (CSCO) 2023: esophageal cancer,2023

3. Esophagus and esophagogastric junction;Rice,2017

4. Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous cell carcinoma of esophagus: a phase III randomized trial;Zhao;J Thorac Oncol,2015

5. Adjuvant therapy after neoadjuvant therapy for esophageal cancer: who needs it?;Raja;Ann Surg,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP